NeoGenomics Stock Soars on Upgrades and Strong Earnings

NeoGenomics Stock Jumps on Analyst Upgrades and Earnings Beat

NeoGenomics Inc. (NASDAQ:NEO) shares experienced a significant 7.43% increase following positive first-quarter financial results and subsequent rating upgrades from two analyst firms, Leerink and Benchmark.

Strong Financial Performance Drives Confidence

The cancer diagnostics company reported first-quarter revenue of $187 million, an 11% year-over-year increase that surpassed analyst expectations of $184.53 million. The growth was primarily driven by strong performance in its next-generation sequencing and clinical testing divisions. Adjusted EBITDA also saw a substantial 27% climb to $9 million, while earnings per share met forecasts at $0.01.

Analyst Upgrades Signal Bullish Outlook

The strong quarterly report prompted positive revisions from Wall Street. Leerink analysts upgraded NeoGenomics to Outperform from Market Perform, more than doubling their price target to $25 from $12. They cited the company's strong momentum and attractive valuation. Benchmark analysts also upgraded the stock to a Buy rating, describing the quarter as solid.

Summary and Future Outlook

The dual catalyst of a solid earnings report and bullish analyst sentiment has propelled NeoGenomics stock higher. Investors will now watch to see if the company can maintain its growth momentum and profitability, which analysts believe is putting it back on track.

FAQ

Q: Why did NeoGenomics stock increase?

A: The stock rose due to strong first-quarter earnings and rating upgrades from both Leerink and Benchmark analysts.

Q: What was Leerink's new price target for NeoGenomics?

A: Leerink raised its price target for NEO to $25, up from the previous target of $12.

Source: Investing.com